The European Medicines Agency (EMA) has started the rapid test procedure for the vaccine from the Tübingen manufacturer Curevac. The decision is based on the preliminary results of laboratory tests and clinical studies. This makes it clear that the vaccine stimulates the production of antibodies against the coronavirus.
Online since today, 12.11 p.m.
The authority evaluates the data according to the so-called rolling review process.
The data and results are continuously checked, even if the test series has not yet been completed and no application for approval in the EU has been submitted.
The procedure is faster than conventional tests, but just as carefully as the EMA announced. How long the exam will take is unclear.
As soon as there is enough evidence that the vaccine is effective, the manufacturer can apply for marketing authorization in the EU.
The EMA experts give a recommendation on this.
The EU Commission then makes a formal decision. Two other vaccine testing procedures are currently underway. So far, three vaccines have been approved in the EU.